排序方式: 共有2条查询结果,搜索用时 0 毫秒
1
1.
Borgoyakova M. B. Karpenko L. I. Rudometov A. P. Shanshin D. V. Isaeva A. A. Nesmeyanova V. S. Volkova N. V. Belenkaya S. V. Murashkin D. E. Shcherbakov D. N. Volosnikova E. A. Starostina E. V. Orlova L. A. Danilchenko N. V. Zaikovskaya A. V. Pyankov O. V. Ilyichev A. A. 《Molecular Biology》2021,55(6):889-898
Molecular Biology - The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid... 相似文献
2.
S. V. Podlesnykh D. V. Shanshin E. A. Kolosova D. E. Murashkin O. N. Shaprova D. N. Shcherbakov A. I. Chapoval 《Russian Journal of Bioorganic Chemistry》2018,44(2):150-157
Current strategy for the blockade of molecules inhibiting T-cell immunity, the immune checkpoints (ICP), such as CTLA-4, PD-1, and B7-H1(PD-L1), using monoclonal antibodies (mAbs), showed significant clinical effects in cancer immunotherapy. In this kind of therapy, antibodies do not kill tumor cells directly, but block inhibitory signals for T lymphocytes, resulting in activation of the immune response cascade that eliminate malignant cells and lead to tumor degradation. However, the mAb preparations have some limitations, and the development of new low-molecular-weight antagonists (for example, peptides) is an important issue. In this study, we used peptide microarrays and phage display libraries to search for peptides that interact with the immune checkpoints. We found peptides that specifically bind CTLA-4, PD-1, B7-1, B7-2 and B7-H1(PD-L1) which play important role in the regulation of the immune responses. These synthetic peptides can be applied to the development of new immunomodulating drugs for cancer immunotherapy. 相似文献
1